A recent deal I saw was structured exactly like some are saying IPIX will fund P3 for OM for an EU / US trial. I forget which company that was. If brilacidin proves itself IPIX would still be the majority beneficiary making the dilution worth the risk imo. And would put IPIX in a very big light. There's also a chance that whoever the partner is puts up their own money for a piece of the pie as well. I'd hate to see a deal that basically hands over the drug for peanuts like the IBD deal with Alfa. And so far from what I've seen that's not going to happen.
So, till we see how it's funded, I'm pretty much just a reed in the wind.
I'm also in the mindset that we may see a NT filing for the 10-K. That possibility comes to me by the way the bid has been being taken out this week. Watching closely and have the funds to take advantage.